Chemotherapy and Recombinant Interferon Alfa-2B Followed by Mobilized Donor Lymphocyte Infusion in Treating Patients with Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia after Donor Stem Cell Transplant

Inclusion Criteria

• Relapsed acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) >= 60 days after allogeneic stem cell transplant (SCT)
• Evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment)
• Karnofsky performance status >= 60%
• Absence of active GVHD and off immunosuppression; subjects on tapering prednisone will be eligible if their dose is 0.25 mg/kg or less and being actively tapered; we suggest a 28 day waiting period off of immunosuppression but some subjects with rapidly progressive disease may need to be treated before 30 days and will still be eligible
• Creatinine (Cr) =< 2 mg/dL
• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN)
• Direct bilirubin (bili) < 3 x ULN
• Matched sibling or un-related donor (A, B, C, and DR) available to undergo leukopheresis
• Subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing
• Willing to provide blood samples for research purposes
• Willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility – tubal ligation or vasectomy in patient or partner, or oral contraceptive)
• DONOR: Human leukocyte antigen (HLA) identical to recipient subject
• DONOR: Considered medically eligible for leukopheresis procedure by independent donor physician (University of Pennsylvania physician who is not the recipient’s primary transplant physician for related donors; physician designated by National Marrow Donor Program for unrelated donors)
• DONOR: Considered medically eligible to receive G-CSF (filgrastim) by independent donor physician

Exclusion Criteria

• Prior cell therapy for relapse within the past 90 days
• Requirement for active immunosuppression to treat GVHD
• Pregnant or lactating women
• Uncontrolled active infection
• Any uncontrolled active medical disorder that would preclude participation
• Donor does not consent to or is unable to participate in this trial
• DONOR: Unable to participate in a leukopheresis procedure or receive G-CSF (filgrastim)